Compare
Aprea Therapeutics, Inc. vs Cellectar Biosciences, Inc. vs Lipocine Inc. vs Impact Biomedical Inc.
| Latest fiscal year | Aprea Therapeutics, Inc. APRE | Cellectar Biosciences, Inc. CLRB | Lipocine Inc. LPCN | Impact Biomedical Inc. IBO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $1.98M | $32.0K |
| Revenue growth (YoY) | n/a | n/a | -82.3% | n/a |
| Gross margin | n/a | n/a | n/a | n/m (computed) |
| Operating margin | n/a | n/a | -524.7% | n/m |
| Net margin | n/a | n/a | -487.1% | n/m |
| Net income | -$12.60M | -$21.79M | -$9.63M | -$11.84M |
| EPS (Diluted) | -$1.93 | -$8.35 | -$1.69 | -$0.38 |
| Operating cash flow | -$12.89M | -$23.12M | -$9.76M | -$1.89M |
| Free cash flow | n/a | -$23.12M | n/a | n/a |
| Cash & equivalents | $14.60M | $13.20M | $5.21M | $3.0K |
| Total assets | $15.93M | $14.98M | $17.01M | $17.41M |
| Total liabilities | n/a | $5.06M | $2.53M | $1.85M |
| Shareholders' equity | $12.44M | $8.54M | $14.48M | $12.61M |
| Return on year-end equity | -101.3% | -255.2% | -66.5% | -93.9% |
| Shares outstanding | 8.19M | 4.24M | 6.16M | 104.62M |
Revenue, most recent five fiscal years
| Fiscal year | Aprea Therapeutics, Inc. | Cellectar Biosciences, Inc. | Lipocine Inc. | Impact Biomedical Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $1.98M Ended 2025-12-31 | $32.0K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $11.20M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | -$2.85M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $500.0K Ended 2022-12-31 | $50.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $16.14M Ended 2021-12-31 | n/a |